{
      "Rank": 761,
      "Acronym": [
            "FTD_ET-STEM"
      ],
      "AgreementOtherDetails": [],
      "AgreementPISponsorEmployee": [],
      "AgreementRestrictionType": [],
      "AgreementRestrictiveAgreement": [],
      "ArmGroupDescription": [
            "injected with 3x10^7 cells/2mL of ET-STEM to intraventricular space via an Ommaya reservoir. repeated 3 times at 4 week intervals"
      ],
      "ArmGroupInterventionName": [
            "Drug: ET-STEM"
      ],
      "ArmGroupLabel": [
            "Treatment Arm"
      ],
      "ArmGroupType": [
            "Experimental"
      ],
      "AvailIPDComment": [],
      "AvailIPDId": [],
      "AvailIPDType": [],
      "AvailIPDURL": [],
      "BaselineCategoryTitle": [],
      "BaselineClassDenomCountGroupId": [],
      "NCTId": [
            "NCT05315661"
      ],
      "BaselineClassDenomCountValue": [],
      "BaselineClassDenomUnits": [],
      "BaselineClassTitle": [],
      "BaselineDenomCountGroupId": [],
      "BaselineDenomCountValue": [],
      "BaselineDenomUnits": [],
      "BaselineGroupDescription": [],
      "BaselineGroupId": [],
      "BaselineGroupTitle": [],
      "BaselineMeasureCalculatePct": [],
      "BaselineMeasureDenomCountGroupId": [],
      "BaselineMeasureDenomCountValue": [],
      "BaselineMeasureDenomUnits": [],
      "BaselineMeasureDenomUnitsSelected": [],
      "BaselineMeasureDescription": [],
      "BaselineMeasureDispersionType": [],
      "BaselineMeasureParamType": [],
      "BaselineMeasurePopulationDescription": [],
      "BaselineMeasureTitle": [],
      "BaselineMeasureUnitOfMeasure": [],
      "BaselineMeasurementComment": [],
      "BaselineMeasurementGroupId": [],
      "BaselineMeasurementLowerLimit": [],
      "BaselineMeasurementSpread": [],
      "BaselineMeasurementUpperLimit": [],
      "BaselineMeasurementValue": [],
      "BaselinePopulationDescription": [],
      "BaselineTypeUnitsAnalyzed": [],
      "BioSpecDescription": [],
      "BioSpecRetention": [],
      "BriefSummary": [
            "The primary purpose of this study is to evaluate the safety and the tolerability of 3 repeated doses of ET-STEM (Mesenchymal stem cells preconditioned with ethionamide) in patients with FTD."
      ],
      "BriefTitle": [
            "The Safety and The Efficacy Evaluation of ET-STEM in Patients With Frontotemporal Dementia"
      ],
      "CentralContactEMail": [
            "evekhj@gmail.com"
      ],
      "CentralContactName": [
            "HeeJin Kim",
            "HeeJin Kim"
      ],
      "CentralContactPhone": [
            "82-10-8654-7347",
            "82-10-8654-7347"
      ],
      "CentralContactPhoneExt": [],
      "CentralContactRole": [
            "Contact",
            "Contact"
      ],
      "CollaboratorClass": [],
      "CollaboratorName": [],
      "CompletionDate": [
            "December 31, 2026"
      ],
      "CompletionDateType": [
            "Anticipated"
      ],
      "Condition": [
            "Frontotemporal Dementia"
      ],
      "ConditionAncestorId": [
            "D000001927",
            "D000002493",
            "D000009422",
            "D000019965",
            "D000001523",
            "D000019636",
            "D000057174",
            "D000057177",
            "D000057165",
            "D000008659",
            "D000001037",
            "D000013064",
            "D000007806",
            "D000003147",
            "D000019954",
            "D000009461"
      ],
      "ConditionAncestorTerm": [
            "Brain Diseases",
            "Central Nervous System Diseases",
            "Nervous System Diseases",
            "Neurocognitive Disorders",
            "Mental Disorders",
            "Neurodegenerative Diseases",
            "Frontotemporal Lobar Degeneration",
            "TDP-43 Proteinopathies",
            "Proteostasis Deficiencies",
            "Metabolic Diseases",
            "Aphasia",
            "Speech Disorders",
            "Language Disorders",
            "Communication Disorders",
            "Neurobehavioral Manifestations",
            "Neurologic Manifestations"
      ],
      "ConditionBrowseBranchAbbrev": [
            "BC10",
            "BXM",
            "All",
            "BC23",
            "BC18",
            "Rare"
      ],
      "ConditionBrowseBranchName": [
            "Nervous System Diseases",
            "Behaviors and Mental Disorders",
            "All Conditions",
            "Symptoms and General Pathology",
            "Nutritional and Metabolic Diseases",
            "Rare Diseases"
      ],
      "ConditionBrowseLeafAsFound": [
            "Dementia",
            "Frontotemporal Dementia",
            "Frontotemporal Dementia",
            "Frontotemporal Dementia",
            "Frontotemporal Dementia",
            "Frontotemporal Dementia",
            "Frontotemporal Dementia",
            "Frontotemporal Dementia"
      ],
      "ConditionBrowseLeafId": [
            "M6056",
            "M20082",
            "M21683",
            "M27915",
            "M3504",
            "M4356",
            "M4894",
            "M20989",
            "M13625",
            "M3967",
            "M20711",
            "M27909",
            "M27912",
            "M27900",
            "M10791",
            "M15016",
            "M9975",
            "M5526",
            "M20979",
            "M11556",
            "T4710",
            "T2399",
            "T2400",
            "T5168",
            "T704"
      ],
      "ConditionBrowseLeafName": [
            "Dementia",
            "Aphasia, Primary Progressive",
            "Pick Disease of the Brain",
            "Frontotemporal Dementia",
            "Aphasia",
            "Brain Diseases",
            "Central Nervous System Diseases",
            "Neurocognitive Disorders",
            "Psychotic Disorders",
            "Mental Disorders",
            "Neurodegenerative Diseases",
            "Frontotemporal Lobar Degeneration",
            "TDP-43 Proteinopathies",
            "Proteostasis Deficiencies",
            "Metabolic Diseases",
            "Speech Disorders",
            "Language Disorders",
            "Communication Disorders",
            "Neurobehavioral Manifestations",
            "Neurologic Manifestations",
            "Primary Progressive Aphasia",
            "Frontotemporal Dementia",
            "Frontotemporal Dementia, Ubiquitin-positive",
            "Semantic Dementia",
            "Behavioral Variant of Frontotemporal Dementia"
      ],
      "ConditionBrowseLeafRelevance": [
            "high",
            "high",
            "high",
            "high",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "high",
            "high",
            "high",
            "high",
            "low"
      ],
      "ConditionMeshId": [
            "D000003704",
            "D000057180",
            "D000018888",
            "D000020774"
      ],
      "ConditionMeshTerm": [
            "Dementia",
            "Frontotemporal Dementia",
            "Aphasia, Primary Progressive",
            "Pick Disease of the Brain"
      ],
      "DelayedPosting": [],
      "DesignAllocation": [
            "N/A"
      ],
      "DesignInterventionModel": [
            "Single Group Assignment"
      ],
      "DesignInterventionModelDescription": [
            "Single Group"
      ],
      "DesignMasking": [
            "None (Open Label)"
      ],
      "DesignMaskingDescription": [],
      "DesignObservationalModel": [],
      "DesignPrimaryPurpose": [
            "Treatment"
      ],
      "DesignTimePerspective": [],
      "DesignWhoMasked": [],
      "DetailedDescription": [
            "Subjects with FTD, who signed the informed consent form and meet the eligibility criteria will undergo Ommaya reservoir insertion. 2 weeks after Ommaya reservoir insertion, the subjects will be injected with 3x10^7 cells/2mL of ET-STEM to intraventricular space via an Ommaya reservoir. The injection will be repeated 3 times at 4 week intervals. The subjects will be hospitalized for 24 hours and observed for acute adverse events. 4 weeks after the 3rd injection, safety and potential efficacy will be assessed."
      ],
      "DispFirstPostDate": [],
      "DispFirstPostDateType": [],
      "DispFirstSubmitDate": [],
      "DispFirstSubmitQCDate": [],
      "EligibilityCriteria": [
            "Inclusion Criteria:\n\nKorean male or female at 40-85 years of age\n\nDiagnosis of one of the 3 subtyes of FTD according to the diagnostic criteria for 3 subtypes of FTD\n\n\u2460 Probable bvFTD (behavior variant FTD)\n\n\u2461 svPPA (semantic variant primary progressive aphasia)\n\n\u2462 nfvPPA (nonfluent/agrammatic variant primary progressive aphasia)\n\nK-MMSE \u2265 10\nSubjects with trusted caregivers who regularly contact the subjects and can accompany the subjects when visiting the hospital.\nNegative result of amyloid PET imaging\nA subject who is informed of the clinical trial and signs a consent form (If unable to sign, a consent from a legally acceptable representative is required)\n\nExclusion Criteria:\n\nSubjects with dementia cause by other than FTD (i.e. infection of central nervous system, Creutzfeld-Jacob disease, severer head trauma, Huntington's disease, Parkinson's disease, Alzheimer's disease and vascular dementia)\nSubjects with psychological disorder. (i.e. depression, schizophrenia , bipolar disorder, etc) (except for subjects who were misdiagnosed with psychological disease due to the initial neuropsychiatric symptoms of FTD)\nSubjects with uncontrolled hypotension, hypertension, diabetes and thyroid disease.\nSubjects with a cancer (including brain tumor)\nSubjects with bleeding disorder\nWoman of childbearing age who refused to practice medically acceptable contraceptive method (post menopausal patient with no menstruation for at least 12 months is considered as infertile)\nPregnant or lactating females\nHistory of stroke within 3 months prior to study enrollment\nSubstance/alcohol abuse 1\nContraindicated for any of the tests performed during the clinical trial period(for example, MRI, CT,PET)\nA subject in whom Ommaya reservoir insertion and general anesthesia are considered difficult\nAbnormal Laboratory findings at Screening\nSuspected active lung disease based on chest X-ray at Screening\nPositive hepatitis B nuclear antibody and hpatitis C antibody\nSubjects who the principal investigator considers inappropriate for participation in the study due to the possible harmful effect on the subjects,difficulty in study completion, or previous or current medical conditions that may disturb evaluation of study results\nSubjects who the principal investigator considers impossible to comply with clinical research procedures."
      ],
      "EnrollmentCount": [
            "12"
      ],
      "EnrollmentType": [
            "Anticipated"
      ],
      "EventGroupDeathsNumAffected": [],
      "EventGroupDeathsNumAtRisk": [],
      "EventGroupDescription": [],
      "EventGroupId": [],
      "EventGroupOtherNumAffected": [],
      "EventGroupOtherNumAtRisk": [],
      "EventGroupSeriousNumAffected": [],
      "EventGroupSeriousNumAtRisk": [],
      "EventGroupTitle": [],
      "EventsDescription": [],
      "EventsFrequencyThreshold": [],
      "EventsTimeFrame": [],
      "ExpAccTypeIndividual": [],
      "ExpAccTypeIntermediate": [],
      "ExpAccTypeTreatment": [],
      "ExpandedAccessNCTId": [],
      "ExpandedAccessStatusForNCTId": [],
      "FDAAA801Violation": [],
      "FlowAchievementComment": [],
      "FlowAchievementGroupId": [],
      "FlowAchievementNumSubjects": [],
      "FlowAchievementNumUnits": [],
      "FlowDropWithdrawComment": [],
      "FlowDropWithdrawType": [],
      "FlowGroupDescription": [],
      "FlowGroupId": [],
      "FlowGroupTitle": [],
      "FlowMilestoneComment": [],
      "FlowMilestoneType": [],
      "FlowPeriodTitle": [],
      "FlowPreAssignmentDetails": [],
      "FlowReasonComment": [],
      "FlowReasonGroupId": [],
      "FlowReasonNumSubjects": [],
      "FlowReasonNumUnits": [],
      "FlowRecruitmentDetails": [],
      "FlowTypeUnitsAnalyzed": [],
      "Gender": [
            "All"
      ],
      "GenderBased": [],
      "GenderDescription": [],
      "HasExpandedAccess": [
            "No"
      ],
      "HealthyVolunteers": [
            "No"
      ],
      "IPDSharing": [
            "No"
      ],
      "IPDSharingAccessCriteria": [],
      "IPDSharingDescription": [],
      "IPDSharingInfoType": [],
      "IPDSharingTimeFrame": [],
      "IPDSharingURL": [],
      "InterventionAncestorId": [],
      "InterventionAncestorTerm": [],
      "InterventionArmGroupLabel": [
            "Treatment Arm"
      ],
      "InterventionBrowseBranchAbbrev": [
            "Infe",
            "Lipd",
            "All"
      ],
      "InterventionBrowseBranchName": [
            "Anti-Infective Agents",
            "Lipid Regulating Agents",
            "All Drugs and Chemicals"
      ],
      "InterventionBrowseLeafAsFound": [],
      "InterventionBrowseLeafId": [
            "M7300"
      ],
      "InterventionBrowseLeafName": [
            "Ethionamide"
      ],
      "InterventionBrowseLeafRelevance": [
            "low"
      ],
      "InterventionDescription": [
            "mesenchymal stem cells preconditioned with ethionamide"
      ],
      "InterventionMeshId": [],
      "InterventionMeshTerm": [],
      "InterventionName": [
            "ET-STEM"
      ],
      "InterventionOtherName": [],
      "InterventionType": [
            "Drug"
      ],
      "IsFDARegulatedDevice": [
            "No"
      ],
      "IsFDARegulatedDrug": [
            "No"
      ],
      "IsPPSD": [],
      "IsUSExport": [],
      "IsUnapprovedDevice": [],
      "Keyword": [],
      "LargeDocDate": [],
      "LargeDocFilename": [],
      "LargeDocHasICF": [],
      "LargeDocHasProtocol": [],
      "LargeDocHasSAP": [],
      "LargeDocLabel": [],
      "LargeDocTypeAbbrev": [],
      "LargeDocUploadDate": [],
      "LastKnownStatus": [],
      "LastUpdatePostDate": [
            "May 13, 2022"
      ],
      "LastUpdatePostDateType": [
            "Actual"
      ],
      "LastUpdateSubmitDate": [
            "May 11, 2022"
      ],
      "LeadSponsorClass": [
            "OTHER"
      ],
      "LeadSponsorName": [
            "Samsung Medical Center"
      ],
      "LimitationsAndCaveatsDescription": [],
      "LocationCity": [],
      "LocationContactEMail": [],
      "LocationContactName": [],
      "LocationContactPhone": [],
      "LocationContactPhoneExt": [],
      "LocationContactRole": [],
      "LocationCountry": [],
      "LocationFacility": [],
      "LocationState": [],
      "LocationStatus": [],
      "LocationZip": [],
      "MaximumAge": [
            "85 Years"
      ],
      "MinimumAge": [
            "40 Years"
      ],
      "NCTIdAlias": [],
      "OfficialTitle": [
            "Clinical Assessment on the Safety and Potential Efficacy of Mesenchymal Stem Cells Preconditioned With Ethionamide (ET-STEM) in Patients With Frontotemporal Dementia (FTD)"
      ],
      "OrgClass": [
            "OTHER"
      ],
      "OrgFullName": [
            "Samsung Medical Center"
      ],
      "OrgStudyId": [
            "2022-02-089"
      ],
      "OrgStudyIdDomain": [],
      "OrgStudyIdLink": [],
      "OrgStudyIdType": [],
      "OtherEventAssessmentType": [],
      "OtherEventNotes": [],
      "OtherEventOrganSystem": [],
      "OtherEventSourceVocabulary": [],
      "OtherEventStatsGroupId": [],
      "OtherEventStatsNumAffected": [],
      "OtherEventStatsNumAtRisk": [],
      "OtherEventStatsNumEvents": [],
      "OtherEventTerm": [],
      "OtherOutcomeDescription": [],
      "OtherOutcomeMeasure": [],
      "OtherOutcomeTimeFrame": [],
      "OutcomeAnalysisCILowerLimit": [],
      "OutcomeAnalysisCILowerLimitComment": [],
      "OutcomeAnalysisCINumSides": [],
      "OutcomeAnalysisCIPctValue": [],
      "OutcomeAnalysisCIUpperLimit": [],
      "OutcomeAnalysisCIUpperLimitComment": [],
      "OutcomeAnalysisDispersionType": [],
      "OutcomeAnalysisDispersionValue": [],
      "OutcomeAnalysisEstimateComment": [],
      "OutcomeAnalysisGroupDescription": [],
      "OutcomeAnalysisGroupId": [],
      "OutcomeAnalysisNonInferiorityComment": [],
      "OutcomeAnalysisNonInferiorityType": [],
      "OutcomeAnalysisOtherAnalysisDescription": [],
      "OutcomeAnalysisPValue": [],
      "OutcomeAnalysisPValueComment": [],
      "OutcomeAnalysisParamType": [],
      "OutcomeAnalysisParamValue": [],
      "OutcomeAnalysisStatisticalComment": [],
      "OutcomeAnalysisStatisticalMethod": [],
      "OutcomeAnalysisTestedNonInferiority": [],
      "OutcomeCategoryTitle": [],
      "OutcomeClassDenomCountGroupId": [],
      "OutcomeClassDenomCountValue": [],
      "OutcomeClassDenomUnits": [],
      "OutcomeClassTitle": [],
      "OutcomeDenomCountGroupId": [],
      "OutcomeDenomCountValue": [],
      "OutcomeDenomUnits": [],
      "OutcomeGroupDescription": [],
      "OutcomeGroupId": [],
      "OutcomeGroupTitle": [],
      "OutcomeMeasureAnticipatedPostingDate": [],
      "OutcomeMeasureCalculatePct": [],
      "OutcomeMeasureDenomUnitsSelected": [],
      "OutcomeMeasureDescription": [],
      "OutcomeMeasureDispersionType": [],
      "OutcomeMeasureParamType": [],
      "OutcomeMeasurePopulationDescription": [],
      "OutcomeMeasureReportingStatus": [],
      "OutcomeMeasureTimeFrame": [],
      "OutcomeMeasureTitle": [],
      "OutcomeMeasureType": [],
      "OutcomeMeasureTypeUnitsAnalyzed": [],
      "OutcomeMeasureUnitOfMeasure": [],
      "OutcomeMeasurementComment": [],
      "OutcomeMeasurementGroupId": [],
      "OutcomeMeasurementLowerLimit": [],
      "OutcomeMeasurementSpread": [],
      "OutcomeMeasurementUpperLimit": [],
      "OutcomeMeasurementValue": [],
      "OverallOfficialAffiliation": [
            "Samsung Medical Center"
      ],
      "OverallOfficialName": [
            "HeeJin Kim"
      ],
      "OverallOfficialRole": [
            "Principal Investigator"
      ],
      "OverallStatus": [
            "Not yet recruiting"
      ],
      "OversightHasDMC": [
            "No"
      ],
      "PatientRegistry": [],
      "Phase": [
            "Phase 1"
      ],
      "PointOfContactEMail": [],
      "PointOfContactOrganization": [],
      "PointOfContactPhone": [],
      "PointOfContactPhoneExt": [],
      "PointOfContactTitle": [],
      "PrimaryCompletionDate": [
            "December 31, 2026"
      ],
      "PrimaryCompletionDateType": [
            "Anticipated"
      ],
      "PrimaryOutcomeDescription": [
            "incidence rate of DLT (Dose limiting toxicity)",
            "all potentially treated subjects to assess the safety"
      ],
      "PrimaryOutcomeMeasure": [
            "To determine DLT (Dose limiting toxicity)",
            "adverse events as assessed by CTCAE v5.0"
      ],
      "PrimaryOutcomeTimeFrame": [
            "First 3-week cycle of treatment",
            "up to 5years"
      ],
      "ReferenceCitation": [],
      "ReferencePMID": [],
      "ReferenceType": [],
      "RemovedCountry": [],
      "ResponsiblePartyInvestigatorAffiliation": [
            "Samsung Medical Center"
      ],
      "ResponsiblePartyInvestigatorFullName": [
            "Hee Jin Kim"
      ],
      "ResponsiblePartyInvestigatorTitle": [
            "assistant professor"
      ],
      "ResponsiblePartyOldNameTitle": [],
      "ResponsiblePartyOldOrganization": [],
      "ResponsiblePartyType": [
            "Principal Investigator"
      ],
      "ResultsFirstPostDate": [],
      "ResultsFirstPostDateType": [],
      "ResultsFirstPostedQCCommentsDate": [],
      "ResultsFirstPostedQCCommentsDateType": [],
      "ResultsFirstSubmitDate": [],
      "ResultsFirstSubmitQCDate": [],
      "RetractionPMID": [],
      "RetractionSource": [],
      "SamplingMethod": [],
      "SecondaryId": [],
      "SecondaryIdDomain": [],
      "SecondaryIdLink": [],
      "SecondaryIdType": [],
      "SecondaryOutcomeDescription": [
            "response rate, no change or improvement on ADAS cog 13 score",
            "Change from the baseline in CDR-SB, min 0, max 24, higher scores mean a worse outcome",
            "Change from the baseline in ADCS-iADL, min 0, max78, higher scores mean a better outcome",
            "Change from the baseline in CGA-NPI, min 0, max 144, higher scores mean a worse outcome",
            "Change from the baseline in CSF biomarkers",
            "Korean Mini-Mental State Examination(MMSE), min 0, max 30, higher scores mean a better outcome"
      ],
      "SecondaryOutcomeMeasure": [
            "ADAS-Cog 13 response rate",
            "The Clinical Dementia Rating Sum of Boxes",
            "Alzheimer's Disease Cooperative Study- instrumental items of the Activities of Daily Living Inventory",
            "Caregiver-administered Neuropsychiatric Inventory",
            "preliminary efficacy",
            "K-MMSE"
      ],
      "SecondaryOutcomeTimeFrame": [
            "Screening, after the first administration12weeks, 48weeks, 96weeks, 144weeks, 192weeks, 240weeks",
            "Screening, after the first administration12weeks, 48weeks, 96weeks, 144weeks, 192weeks, 240weeks",
            "the first administration12weeks, 48weeks, 96weeks, 144weeks, 192weeks, 240weeks",
            "the first administration12weeks, 48weeks, 96weeks, 144weeks, 192weeks, 240weeks",
            "up to 12weeks",
            "the first administration12weeks, 48weeks, 96weeks, 144weeks, 192weeks, 240weeks"
      ],
      "SeeAlsoLinkLabel": [],
      "SeeAlsoLinkURL": [],
      "SeriousEventAssessmentType": [],
      "SeriousEventNotes": [],
      "SeriousEventOrganSystem": [],
      "SeriousEventSourceVocabulary": [],
      "SeriousEventStatsGroupId": [],
      "SeriousEventStatsNumAffected": [],
      "SeriousEventStatsNumAtRisk": [],
      "SeriousEventStatsNumEvents": [],
      "SeriousEventTerm": [],
      "StartDate": [
            "May 17, 2022"
      ],
      "StartDateType": [
            "Anticipated"
      ],
      "StatusVerifiedDate": [
            "May 2022"
      ],
      "StdAge": [
            "Adult",
            "Older Adult"
      ],
      "StudyFirstPostDate": [
            "April 7, 2022"
      ],
      "StudyFirstPostDateType": [
            "Actual"
      ],
      "StudyFirstSubmitDate": [
            "March 1, 2022"
      ],
      "StudyFirstSubmitQCDate": [
            "March 30, 2022"
      ],
      "StudyPopulation": [],
      "StudyType": [
            "Interventional"
      ],
      "SubmissionMCPReleaseN": [],
      "SubmissionReleaseDate": [],
      "SubmissionResetDate": [],
      "SubmissionUnreleaseDate": [],
      "TargetDuration": [],
      "UnpostedEventDate": [],
      "UnpostedEventType": [],
      "UnpostedResponsibleParty": [],
      "VersionHolder": [
            "October 10, 2022"
      ],
      "WhyStopped": []
}